{"id":2380,"date":"2025-01-10T11:32:46","date_gmt":"2025-01-10T08:32:46","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=2380"},"modified":"2025-03-27T16:49:38","modified_gmt":"2025-03-27T13:49:38","slug":"nippon-shinyaku-releases-first-clinical-trial-first-in-human-of-brogidirsen-ns-089-ncnp-02-for-the-treatment-of-duchenne","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/tr\/nippon-shinyaku-releases-first-clinical-trial-first-in-human-of-brogidirsen-ns-089-ncnp-02-for-the-treatment-of-duchenne\/","title":{"rendered":"Nippon Shinyaku, Duchenne Tedavisi \u0130\u00e7in Brogidirsen NS-089\/NCNP-02&#039;nin \u0130lk Klinik Denemesini (\u0130nsan \u00dczerinde \u0130lk) Yay\u0131mlad\u0131"},"content":{"rendered":"<p class=\"wp-block-paragraph\">Ulusal N\u00f6roloji ve Psikiyatri Merkezi, Cell Reports Medicine&#039;de, &quot;brogidirsen&quot; olarak bilinen NS-089\/NCNP-02 i\u00e7in ara\u015ft\u0131rmac\u0131 taraf\u0131ndan ba\u015flat\u0131lan bir denemenin sonu\u00e7lar\u0131n\u0131 ayr\u0131nt\u0131lar\u0131yla a\u00e7\u0131klayan bir ara\u015ft\u0131rma makalesinin yay\u0131nland\u0131\u011f\u0131n\u0131 duyurdu. Nippon Shinyaku Co., Ltd. ile birlikte geli\u015ftirilen Duchenne kas distrofisi (DMD) i\u00e7in bu yenilik\u00e7i tedavi, ekzon 44 atlama terapisinde \u00f6nemli bir ilerlemeyi temsil ediyor.<\/p>\n\n\n\n<div class=\"wp-block-rank-math-toc-block\" id=\"rank-math-toc\"><h2>\u0130\u00e7indekiler<\/h2><nav><ul><li><a href=\"#key-findings-from-brogidirsen-include\">Brogidirsen Klinik Deney Sonu\u00e7lar\u0131<\/a><\/li><li><a href=\"#what-is-brogidirsen\">Brogidirsen nedir?<\/a><\/li><\/ul><\/nav><\/div>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"key-findings-from-brogidirsen-include\">Brogidirsen Klinik Deney Sonu\u00e7lar\u0131<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Brogidirsen, DMD hastalar\u0131nda yap\u0131lan \u00e7al\u0131\u015fmalarda doza ba\u011fl\u0131 distrofin restorasyonunu g\u00f6stermektedir.<\/li>\n\n\n\n<li>Y\u00fcksek doz brogidirsen DMD kohortunda normal distrofin d\u00fczeyinin 24.47%&#039;sine ula\u015ft\u0131.<\/li>\n\n\n\n<li>\u00c7al\u0131\u015fma, stabil veya iyile\u015ftirilmi\u015f motor fonksiyon ve ciddi yan etki olmaks\u0131z\u0131n olumlu bir g\u00fcvenlik profili ile terap\u00f6tik faydalar\u0131 ortaya koydu.<\/li>\n\n\n\n<li>DMD i\u00e7in serum biyobelirte\u00e7leri belirlendi; bunlar aras\u0131nda PADI2, TTN, MYOM2 ve MYLPF yer al\u0131yor.<\/li>\n\n\n\n<li>Brogidirsen&#039;in DMD idrar kaynakl\u0131 h\u00fccrelerde y\u00fcksek etkinlik g\u00f6stermesi insan denemelerini destekliyor.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"what-is-brogidirsen\">Brogidirsen nedir?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Brogidirsen (NS-089\/NCNP-02), Nippon Shinyaku ve NCNP taraf\u0131ndan ortak ke\u015ffedilen bir n\u00fckleik asit ilac\u0131d\u0131r ve ekzon 44 atlamaya yatk\u0131n distrofin gen mutasyonlar\u0131na sahip DMD hastalar\u0131 i\u00e7in terap\u00f6tik bir ila\u00e7 olmas\u0131 beklenmektedir.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Daha fazla bilgi edin:<\/strong> <a href=\"https:\/\/dmdwarrior.com\/tr\/upcoming-exon-44-skipping-therapies-for-dmd\/\" data-type=\"post\" data-id=\"2811\">Duchenne Musk\u00fcler Distrofi Tedavisinde Yakla\u015fan Ekzon 44 Atlama Terapileri<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>The National Center of Neurology and Psychiatry is announced the publication of a research paper in Cell Reports Medicine detailing the results of an investigator-initiated trial for NS-089\/NCNP-02, known as &#8220;brogidirsen.&#8221; This innovative treatment for Duchenne muscular dystrophy (DMD), jointly developed with Nippon Shinyaku Co., Ltd., represents a significant advancement in exon 44 skipping therapy. [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":2383,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[27],"tags":[138,137,141,127,77,142,136,139,140],"class_list":["post-2380","post","type-post","status-publish","format-standard","has-post-thumbnail","category-research","tag-brogidirsen","tag-clinical-trial","tag-exon-44","tag-exon-44-skipping","tag-exon-skipping","tag-japan","tag-nippon-shinyaku","tag-ns-089","tag-ns-089-ncnp-02"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/2380","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/comments?post=2380"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/2380\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media\/2383"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media?parent=2380"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/categories?post=2380"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/tags?post=2380"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}